CD338 antibody | BXP-21
Mouse anti Human CD338, clone BXP-21 recognises an internal epitope of CD338, otherwise known as the Breast Cancer Resistance Protein (BCRP), a ~70 kDa transmembrane half transporter involved in multidrug resistance. Mouse anti Human CD338, clone BXP-21 does not cross react with human MDR1, MRP1 or MRP2 gene products.
- Target Species
- Product Form
- Serum free tissue Culture Supernatant - liquid
- Preservative Stabilisers
0.02% Sodium Azide (NaN3) 0.1% Bovine Serum Albumin
- Fusion protein consisting of the E.coli maltose binding protein and a 126 amino acid part of the CD338 peptide corresponding to aa 271-396 of BCRP according to Genebank accession number AF103796. HPRD:04783
- Approx. Protein Concentrations
- IgG concentration 0.25 mg/ml
- Molecular Weight
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Shelf Life
- Please see label for expiry date
- Q9UNQ0 Related reagents
- Entrez Gene
- ABCG2 Related reagents
- For research purposes only
Applications of CD338 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for CD338 antibody
Maliepaard, M. et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Cancer Res. 61 (8): 3458-64.
Scheffer, G.L. et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Cancer Res. 60 (10): 2589-93.